Business · 05/02/2019Updated: 10/17/2026 · 1 min read
FDA Withdraws Approval of 23 Abbreviated New Drug Applications from Facta Farmaceutici S.p.A., et al.
Summary
The US Food and Drug Administration (FDA) has withdrawn the approval of 23 abbreviated new drug applications (ANDAs) from multiple pharmaceutical companies, including Facta Farmaceutici S.p.A., et al., following written notifications that the drug products were no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →